Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.33 |
| ▸ | ESR1 | P03372 | 6/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11032396 | 0.86 | CYP17A1 (0.35) | ESR2ESR1CYP2C9CYP3A4DGAT1 | |
| SCHEMBL11032393 | 0.86 | CYP17A1 (0.35) | ESR2ESR1CYP2C9CYP3A4DGAT1 | |
| SCHEMBL19844716 | 0.85 | NPC1 (0.33) | ESR2CYP2C9CYP3A4NPC1RAB9A | |
| SCHEMBL11217896 | 0.84 | ESR2 (0.43) | ESR2ESR1CYP2C9CYP3A4DGAT1 | |
| SCHEMBL11217898 | 0.84 | ESR2 (0.43) | ESR2ESR1CYP2C9CYP3A4DGAT1 | |
| SCHEMBL19844735 | 0.84 | ESR2 (0.33) | ESR2CYP2C9DGAT1SOAT1FAAH | |
| SCHEMBL7736554 | 0.83 | FASN (0.35) | ESR2ESR1CYP2C9CYP3A4DGAT1 | |
| SCHEMBL7736550 | 0.83 | FASN (0.35) | ESR2ESR1CYP2C9CYP3A4DGAT1 | |
| SCHEMBL13369630 | 0.83 | ALDH1A1 (0.38) | ESR2ESR1CYP2C9CYP3A4DGAT1 | |
| SCHEMBL11033780 | 0.83 | ESR2 (0.38) | ESR2ESR1CYP2C9CYP3A4DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9093643-B2 | Deformable material and actuator | SEIKO EPSON CORPORATION (JP) | 2015-07-28 | — | — | US | disclosed |
| US-8436117-B2 | Stimuli responsive compound, stimuli responsive compound polymer, actuator and method for manufacturing stimuli responsive compound | SEIKO EPSON CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110196120-A1 | STIMULI RESPONSIVE COMPOUND, STIMULI RESPONSIVE COMPOUND POLYMER, ACTUATOR AND METHOD FOR MANUFACTURING STIMULI RESPONSIVE COMPOUND | SEIKO EPSON CORPORATION (JP) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196120-A1 | STIMULI RESPONSIVE COMPOUND, STIMULI RESPONSIVE COMPOUND POLYMER, ACTUATOR AND METHOD FOR MANUFACTURING STIMULI RESPONSIVE COMPOUND | PUF60, RPSA, RPS16 | ESR2 1798/4885ESR1 1414/4885CYP2C9 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.